|
Q2 FY2027
As of Jul 31, 2026
|
Q1 FY2027
As of Apr 30, 2026
|
Q4 FY2026
As of Jan 31, 2026
|
Q3 FY2026
As of Oct 31, 2025
|
Q2 FY2026
As of Jul 31, 2025
|
Q1 FY2026
As of Apr 30, 2025
|
Q4 FY2025
As of Jan 31, 2025
|
Q3 FY2025
As of Oct 31, 2024
|
Q2 FY2025
As of Jul 31, 2024
|
Q1 FY2025
As of Apr 30, 2024
|
Q4 FY2024
As of Jan 31, 2024
|
Q3 FY2024
As of Oct 31, 2023
|
Q2 FY2024
As of Jul 31, 2023
|
Q1 FY2024
As of Apr 30, 2023
|
Q4 FY2023
As of Jan 31, 2023
|
Q3 FY2023
As of Oct 31, 2022
|
Q2 FY2023
As of Jul 31, 2022
|
Q1 FY2023
As of Apr 30, 2022
|
Q4 FY2022
As of Jan 31, 2022
|
Q3 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash, current | ||||||||||||||||||||
| Accounts receivable, net of allowances of $2,159 and $2,345, respectively | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Costs to obtain revenue contracts, current | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Restricted cash, non-current | ||||||||||||||||||||
| Costs to obtain revenue contracts, non-current | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other long term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable, accrued expenses and other current liabilities | ||||||||||||||||||||
| Unearned revenue, current | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Contingent consideration, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, non-current | ||||||||||||||||||||
| Contingent consideration, non-current | ||||||||||||||||||||
| Long term debt, net | ||||||||||||||||||||
| Other long term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value per share; 50,000,000 shares authorized at July 31, 2026 and January 31, 2026; zero shares issued and outstanding at July 31, 2026 and January 31, 2026 | ||||||||||||||||||||
| Common stock, $0.001 par value per share; 500,000,000 shares authorized at July 31, 2026 and January 31, 2026; 136,537,014 and 158,368,658 shares issued at July 31, 2026 and January 31, 2026, respectively; 99,283,687 and 122,933,027 shares outstanding at July 31, 2026 and January 31, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Treasury stock, at cost | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common stock par value (in dollars per share) | ||||||||||||||||||||
| Common stock shares authorized (in shares) |
Loading...
